Analysis of AstraZeneca
AstraZeneca is the second largest pharmaceutical company in the UK. The company was formed in 1999 by the merger of Swedish-based Astra and UK-based Zeneca Group. AstraZeneca has a strong presence in the US and retains a significant presence in Sweden as a legacy of Astra.
The UK pharmaceutical industry is among the world’s leading manufacturer and exporter of medicines. With the combination of a strong history and favorable environment, the UK pharmaceutical industry has been able to perform better than its potential, despite difficulties faced by the industry throughout the UK and Europe. This growth can be partly attributed to innovative products launched as well as continued promotion of the sector to retain brand recognition.
AstraZeneca has 27 manufacturing sites in 19 countries. The company’s portfolio of marketed medicines include Arimidex, Crestor, Nexium, Seroquel, Symbicort, Pulmicort, Zoladex, Seloken/Toprol-XL, Diprivan and Merrem. On January 31, 2007, AstraZeneca announced its acquisition of Arrow Therapeutics Ltd., a biotechnology company focused on the discovery and development of anti-viral therapies.
Aruvian Research presents Analysis of AstraZeneca. A complete and comprehensive analysis of AstraZeneca, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.
Company analysis from Aruvian includes a history of AstraZeneca, a business segment analysis of the segments AstraZeneca operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.
A financial analysis of AstraZeneca is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.
A SWOT Framework Analysis of AstraZeneca completes this in-depth company analysis.
The UK pharmaceutical industry is among the world’s leading manufacturer and exporter of medicines. With the combination of a strong history and favorable environment, the UK pharmaceutical industry has been able to perform better than its potential, despite difficulties faced by the industry throughout the UK and Europe. This growth can be partly attributed to innovative products launched as well as continued promotion of the sector to retain brand recognition.
AstraZeneca has 27 manufacturing sites in 19 countries. The company’s portfolio of marketed medicines include Arimidex, Crestor, Nexium, Seroquel, Symbicort, Pulmicort, Zoladex, Seloken/Toprol-XL, Diprivan and Merrem. On January 31, 2007, AstraZeneca announced its acquisition of Arrow Therapeutics Ltd., a biotechnology company focused on the discovery and development of anti-viral therapies.
Aruvian Research presents Analysis of AstraZeneca. A complete and comprehensive analysis of AstraZeneca, includes an overview of the industry the company operates in, a PEST Framework Analysis of the industry, and then moves on to analyzing the company itself.
Company analysis from Aruvian includes a history of AstraZeneca, a business segment analysis of the segments AstraZeneca operates through, a look at the organization structure of the company, a geographical operating segments analysis, an analysis of the company’s major competitors.
A financial analysis of AstraZeneca is presented in the report which includes a ratio analysis, basic profit and loss analysis, presentation of the company balance sheet, and much more.
A SWOT Framework Analysis of AstraZeneca completes this in-depth company analysis.
A. EXECUTIVE SUMMARY
B. LOOKING AT THE INDUSTRY
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective
C. INDUSTRY PEST FRAMEWORK ANALYSIS
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects
D. LOOKING AT ASTRAZENECA
D.1 Company Profile
D.2 History of the Company
D.3 Ownership Pattern in the Company
D.4 Organizational Divisions
D.5 Profiling the Key Executives
D.6 Products & Services
E. LOOKING AT BUSINESS
E.1 Business Segments
E.2 Geographical Segments
E.3 Company Subsidiaries
F. ASTRAZENECA: SWOT FRAMEWORK ANALYSIS
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome
G. PROFILING THE COMPETITION
G.1 GlaxoSmithKline
G.1.1 Corporate Profile
G.1.2 Business Segment Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Novartis AG
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Sanofi SA
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis
H. ASTRAZENECA: FINANCIAL ANALYSIS
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit & Loss Statement
H.4 Ratio Analysis
H.4.1 Growth Rates
H.4.2 Price Ratios
H.4.3 Profit Margins
H.4.4 Financial Condition
H.4.5 Investment Returns
H.4.6 Management Efficiency
I. ASTRAZENECA: FUTURE PERSPECTIVE
J. APPENDIX
K. GLOSSARY OF TERMS
B. LOOKING AT THE INDUSTRY
B.1 Industry Definition
B.2 Brief Profile of the Industry
B.3 Impacts on the Industry
B.4 Challenges Facing the Industry
B.5 Future Perspective
C. INDUSTRY PEST FRAMEWORK ANALYSIS
C.1 Political Aspects
C.2 Economic Aspects
C.3 Social Aspects
C.4 Technological Aspects
D. LOOKING AT ASTRAZENECA
D.1 Company Profile
D.2 History of the Company
D.3 Ownership Pattern in the Company
D.4 Organizational Divisions
D.5 Profiling the Key Executives
D.6 Products & Services
E. LOOKING AT BUSINESS
E.1 Business Segments
E.2 Geographical Segments
E.3 Company Subsidiaries
F. ASTRAZENECA: SWOT FRAMEWORK ANALYSIS
F.1 Strengths to Build Upon
F.2 Weaknesses to Overcome
F.3 Opportunities to Exploit
F.4 Threats to Overcome
G. PROFILING THE COMPETITION
G.1 GlaxoSmithKline
G.1.1 Corporate Profile
G.1.2 Business Segment Analysis
G.1.3 Financial Analysis
G.1.4 SWOT Analysis
G.2 Novartis AG
G.2.1 Corporate Profile
G.2.2 Business Segment Analysis
G.2.3 Financial Analysis
G.2.4 SWOT Analysis
G.3 Sanofi SA
G.3.1 Corporate Profile
G.3.2 Business Segment Analysis
G.3.3 Financial Analysis
G.3.4 SWOT Analysis
H. ASTRAZENECA: FINANCIAL ANALYSIS
H.1 Current Financials
H.2 Balance Sheet
H.3 Profit & Loss Statement
H.4 Ratio Analysis
H.4.1 Growth Rates
H.4.2 Price Ratios
H.4.3 Profit Margins
H.4.4 Financial Condition
H.4.5 Investment Returns
H.4.6 Management Efficiency
I. ASTRAZENECA: FUTURE PERSPECTIVE
J. APPENDIX
K. GLOSSARY OF TERMS
